Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models

被引：84

作者：

Brown, Bruce K. ^{[1
]}

Wieczorek, Lindsay ^{[1
]}

Sanders-Buell, Eric ^{[1
]}

Borges, Andrew Rosa ^{[1
]}

Robb, Merlin L. ^{[1
]}

Birx, Deborah L. ^{[2
,3
]}

Michael, Nelson L. ^{[2
]}

McCutchan, Francine E. ^{[1
]}

Polonis, Victoria R. ^{[2
]}

机构：

[1] Henry M Jackson Fdn, Rockville, MD USA

[2] Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA

[3] US Ctr Dis Control, Atlanta, GA USA

来源：

VIROLOGY | 2008年 / 375卷 / 02期

基金：

美国国家卫生研究院;

关键词：

HIV-1; neutralization; cross-clade; primary isolate; pseudovirus; TZM-bl reporter cells;

D O I：

10.1016/j.virol.2008.02.022

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A panel of paired primary virus isolates and envelope pseudoviruses from sixty strains representing six HIV-1 clades was tested for neutralization using pooled, clade-specific plasma in two prominently utilized neutralization platforms: a primary isolate assay using peripheral blood mononuclear cells (PBMC) and a pseudovirus assay using a reporter epithelial cell line. Using the PMBC assay, pairing of the antibody pool against homologous clade viruses generated the highest geometric mean neutralizing antibody titer in 4 out of 6 clades tested, and neutralization patterns showed numerous examples of reciprocal cross-recognition between antibody and viruses of specific clade pairs. In the pseudovirus assay, cross-clade neutralization was more limited, with fewer distinct cross-clade relationships evident. The clade C antibody pool was broadly cross-reactive, neutralizing the greatest number of viruses in both assays. These data highlight the importance of the neutralization assay format employed and suggest that clade C envelopes merit further evaluation for the elicitation of broadly neutralizing antibodies. (c) 2008 Published by Elsevier Inc.

引用

页码：529 / 538

页数：10

共 59 条

[1] RAPID DEVELOPMENT OF ISOLATE-SPECIFIC NEUTRALIZING ANTIBODIES AFTER PRIMARY HIV-1 INFECTION AND CONSEQUENT EMERGENCE OF VIRUS VARIANTS WHICH RESIST NEUTRALIZATION BY AUTOLOGOUS SERA [J].

ALBERT, J ;

ABRAHAMSSON, B ;

NAGY, K ;

AURELIUS, E ;

GAINES, H ;

NYSTROM, G ;

FENYO, EM .

AIDS, 1990, 4 (02) :107-112

[2] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection [J].

Baba, TW ;

Liska, V ;

Hofmann-Lehmann, R ;

Vlasak, J ;

Xu, WD ;

Ayehunie, S ;

Cavacini, LA ;

Posner, MR ;

Katinger, H ;

Stiegler, G ;

Bernacky, BJ ;

Rizvi, TA ;

Schmidt, R ;

Hill, LR ;

Keeling, ME ;

Lu, YC ;

Wright, JE ;

Chou, TC ;

Ruprecht, RM .

NATURE MEDICINE, 2000, 6 (02) :200-206

[3] Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].

Binley, JA ;

Wrin, T ;

Korber, B ;

Zwick, MB ;

Wang, M ;

Chappey, C ;

Stiegler, G ;

Kunert, R ;

Zolla-Pazner, S ;

Katinger, H ;

Petropoulos, CJ ;

Burton, DR .

JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252

[4]

Brown Arthur E., 1998, Southeast Asian Journal of Tropical Medicine and Public Health, V29, P377

[5] Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines [J].

Brown, BK ;

Darden, JM ;

Tovanabutra, S ;

Oblander, T ;

Frost, J ;

Sanders-Buell, E ;

de Souza, MS ;

Birx, DL ;

McCutchan, FE ;

Polonis, VR .

JOURNAL OF VIROLOGY, 2005, 79 (10) :6089-6101

[6] Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: Role of phosphate-binding subsites [J].

Brown, Bruce K. ;

Karasavvas, Nicos ;

Beck, Zoltan ;

Matyas, Gary R. ;

Birx, Deborah L. ;

Polonis, Victoria R. ;

Alving, Carl R. .

JOURNAL OF VIROLOGY, 2007, 81 (04) :2087-2091

[7] Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa [J].

Bures, R ;

Morris, L ;

Williamson, C ;

Ramjee, G ;

Deers, M ;

Fiscus, SA ;

Abdool Karim, SS ;

Montefiori, DC .

JOURNAL OF VIROLOGY, 2002, 76 (05) :2233-2244

[8] HIV vaccine design and the neutralizing antibody problem [J].

Burton, DR ;

Desrosiers, RC ;

Doms, RW ;

Koff, WC ;

Kwong, PD ;

Moore, JP ;

Nabel, GJ ;

Sodroski, J ;

Wilson, IA ;

Wyatt, RT .

NATURE IMMUNOLOGY, 2004, 5 (03) :233-236

[9] Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration [J].

Choudhry, Vidita ;

Zhang, Mei-Yun ;

Harris, Ilia ;

Sidorov, Igor A. ;

Vu, Bang ;

Dimitrov, Antony S. ;

Fouts, Timothy ;

Dimitrov, Dimiter S. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (03) :1107-1115

[10]

Darden JM, 2000, CYTOMETRY, V40, P141, DOI 10.1002/(SICI)1097-0320(20000601)40:2<141::AID-CYTO8>3.3.CO

← 1 2 3 4 5 6 →